915 related articles for article (PubMed ID: 10945843)
21. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Lester PA; Traynor JR
Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
[TBL] [Abstract][Full Text] [Related]
22. beta-Funaltrexamine, a gauge for the recognition site of wildtype and mutant H297Q mu-opioid receptors.
Spivak CE; Beglan CL; Zöllner C; Surratt CK
Synapse; 2003 Jul; 49(1):55-60. PubMed ID: 12710015
[TBL] [Abstract][Full Text] [Related]
23. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
[TBL] [Abstract][Full Text] [Related]
24. mu- but not delta- and kappa-opioid receptors in the ventrolateral orbital cortex mediate opioid-induced antiallodynia in a rat neuropathic pain model.
Zhao M; Wang JY; Jia H; Tang JS
Brain Res; 2006 Mar; 1076(1):68-77. PubMed ID: 16476416
[TBL] [Abstract][Full Text] [Related]
25. Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.
Pitts RC; Allen RM; Walker EA; Dykstra LA
J Pharmacol Exp Ther; 1998 Jun; 285(3):1197-206. PubMed ID: 9618423
[TBL] [Abstract][Full Text] [Related]
26. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
28. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
[TBL] [Abstract][Full Text] [Related]
29. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
30. Discriminative stimulus effects of BW373U86: a nonpeptide ligand with selectivity for delta opioid receptors.
Comer SD; McNutt RW; Chang KJ; De Costa BR; Mosberg HI; Woods JH
J Pharmacol Exp Ther; 1993 Nov; 267(2):866-74. PubMed ID: 8246161
[TBL] [Abstract][Full Text] [Related]
31. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of the antagonistic effects of 6 beta-naltrexol and naltrexone against morphine analgesia].
Yan LD; Gong ZH; Yao XJ; Qin BY
Yao Xue Xue Bao; 2003 Aug; 38(8):578-81. PubMed ID: 14628446
[TBL] [Abstract][Full Text] [Related]
33. Roles of different subtypes of opioid receptors in mediating the ventrolateral orbital cortex opioid-induced inhibition of mirror-neuropathic pain in the rat.
Zhao M; Wang JY; Jia H; Tang JS
Neuroscience; 2007 Feb; 144(4):1486-94. PubMed ID: 17184926
[TBL] [Abstract][Full Text] [Related]
34. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
35. Effects of intracerebroventricular administration of beta-funaltrexamine on DAMGO-stimulated [35S]GTP-gamma-S binding in rat brain sections.
Martin TJ; Sim LJ; Selley DE; deMontis MG; Childers SR
Synapse; 1997 Nov; 27(3):177-82. PubMed ID: 9329153
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
Mjanger E; Yaksh TL
J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
[TBL] [Abstract][Full Text] [Related]
37. Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
Zimmerman DM; Leander JD; Reel JK; Hynes MD
J Pharmacol Exp Ther; 1987 May; 241(2):374-8. PubMed ID: 3033213
[TBL] [Abstract][Full Text] [Related]
38. Studies on kinetics of [3H]beta-funaltrexamine binding to mu opioid receptor.
Liu-Chen LY; Li SX; Tallarida RJ
Mol Pharmacol; 1990 Feb; 37(2):243-50. PubMed ID: 2154672
[TBL] [Abstract][Full Text] [Related]
39. Activity of mu- and delta-selective opioid agonists in the guinea pig ileum preparation: differentiation into peptide and nonpeptide classes with beta-funaltrexamine.
Ward SJ; LoPresti D; James DW
J Pharmacol Exp Ther; 1986 Aug; 238(2):625-31. PubMed ID: 3016244
[TBL] [Abstract][Full Text] [Related]
40. Increase in diazepam binding inhibitor expression by sustained morphine exposure is mediated via mu-opioid receptors in primary cultures of mouse cerebral cortical neurons.
Shibasaki M; Katsura M; Torigoe F; Honda T; Sumimoto A; Tsujimura A; Ohkuma S
J Neurosci Res; 2007 Oct; 85(13):2971-80. PubMed ID: 17638297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
